Durgical
EN
Open the app

Haemophilia care: prophylaxis, inhibitors, non-factor therapy, joints

  • Treatment and support

Severe haemophilia used to mean crippled joints by early adulthood. Regular prevention, started early, now lets most children grow up with healthy joints.

Updated

What it is

Modern haemophilia care aims to stop bleeds before they happen rather than treat them afterwards. In severe disease this means prophylaxis: regular replacement of the missing factor (VIII or IX), or, in haemophilia A, a non-factor drug that does factor VIII's job. Care is planned by a comprehensive haemophilia team (haematologist, nurse, physiotherapist, dentist, social support). The two big threats are joint damage from repeated bleeds and inhibitors, antibodies that make replacement factor useless.

What to know

  • Prophylaxis in severe haemophilia keeps the factor level from ever falling to the point where joints bleed by themselves; it is started in early childhood, ideally before joint damage begins.
  • On-demand treatment (factor only when a bleed happens) prevents death from bleeding but not progressive joint damage.
  • Extended half-life factor concentrates last longer in the blood, so fewer infusions are needed for the same protection.
  • Inhibitors are alloantibodies against infused factor; they are commonest in severe haemophilia A and usually appear in the first months of treatment.
  • Bleeds in a patient with an inhibitor are treated with bypassing agents (recombinant activated factor VII or activated prothrombin complex concentrate), which make thrombin without needing factor VIII or IX.
  • Emicizumab is a bispecific antibody that links factor IXa and factor X, copying the bridging role of factor VIII; it is given under the skin as prophylaxis for haemophilia A with or without inhibitors.
  • Newer agents rebalance clotting by lowering natural anticoagulants (antithrombin or tissue factor pathway inhibitor), and gene therapy that lets the liver make the factor is available in some countries.

How it is done (and why)

  1. Confirm the type (A or B) and severity from the factor level; severe disease is the main candidate for prophylaxis.
  2. Choose the prophylaxis: factor replacement (standard or extended half-life) or, in haemophilia A, a non-factor agent.
  3. Teach home treatment: families and patients learn to infuse or inject so a bleed is treated within minutes, not hours.
  4. Test for an inhibitor early in treatment, before surgery and whenever a bleed responds poorly to the usual factor.
  5. If an inhibitor appears: treat bleeds with bypassing agents and consider immune tolerance induction, frequent regular factor to retrain the immune system.
  6. Protect the joints: treat every joint bleed at once, then physiotherapy; a target joint gets intensified prophylaxis.
  7. Plan dentistry and surgery with the haemophilia team: factor cover, tranexamic acid for mouth bleeding, and the right laboratory test for the drug in use.

Risks and precautions

  • A suspected bleed is treated first and investigated second: give factor (or the agreed agent) before imaging in head injury, deep muscle bleeds or a painful swollen joint.
  • Each joint bleed leaves iron in the synovium, which inflames it and makes it bleed again; three or more spontaneous bleeds in one joint within six months define a target joint.
  • Repeated bleeding ends in haemophilic arthropathy: chronic synovitis, cartilage loss, deformity and pain, most often in knees, elbows and ankles.
  • Iliopsoas bleeds can mimic appendicitis or hip disease and may compress the femoral nerve; forearm and calf bleeds can cause compartment syndrome.
  • Avoid intramuscular injections, aspirin and NSAIDs; vaccines are given under the skin with local pressure.
  • In Colombia haemophilia care is organised through specialised centres and followed as a high-cost disease (Cuenta de Alto Costo).

Monitoring and next step

  • Factor VIII or IX level at diagnosis sets the severity; carriers have their own level measured before delivery or surgery.
  • Inhibitor screen (Bethesda assay) early in treatment, before surgery and whenever treatment seems to fail; the titre guides the choice between factor and bypassing agents.
  • On emicizumab, aPTT-based tests are falsely normal: measure factor VIII with a chromogenic assay using bovine reagents, as the laboratory advises.
  • Joint assessment by examination and, where available, point-of-care ultrasound to tell a bleed from synovitis.
  • Screen for infections acquired from old plasma products (HIV, hepatitis B and C) in older patients.

Common traps

  • Waiting for imaging before giving factor in a head injury: in severe haemophilia the factor goes first and the CT second
  • Treating a breakthrough bleed on emicizumab with activated prothrombin complex concentrate in the usual way: the combination has caused thrombotic microangiopathy and thrombosis, so the team's specific plan is followed
  • Trusting a normal aPTT in a patient on emicizumab: the drug shortens the aPTT regardless of the bleeding risk, so it cannot be used to judge protection
  • Thinking a bleed that does not stop simply needs more of the same factor: a poor response is the classic sign of a new inhibitor and needs testing
  • Assuming emicizumab works in haemophilia B: it replaces the role of factor VIII only

Test yourself

Think of the answer, then tap the question to see it.

A 2-year-old boy with severe haemophilia A falls and hits his head; he seems well. What should be done first, and why?

Give factor VIII (or the agreed agent) at once, then image the head: intracranial bleeding can be silent at first, and waiting for the scan loses time that decides the outcome.

A 9-month-old with severe haemophilia A on factor prophylaxis now bleeds despite his usual infusions. What is the likely cause and the next test?

A new inhibitor (alloantibody against factor VIII), which usually appears early in treatment; measure it with a Bethesda assay.

Why does emicizumab work even when a patient has a factor VIII inhibitor?

It is not factor VIII: it is an antibody that links factor IXa and factor X directly, so the inhibitor has nothing to attack.

Why does on-demand treatment alone fail to protect the joints in severe haemophilia?

Many joint bleeds start silently, and each one leaves iron that inflames the synovium; only keeping the factor up continuously prevents the cycle of bleeding and synovitis.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Treatment of Hemophilia | Hemophilia | CDC (Centers for Disease Control and Prevention, 2026); Hemophilia A (StatPearls (NCBI Bookshelf), 2026); Emicizumab (StatPearls (NCBI Bookshelf), 2023).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.